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Abstract
Individuals with HIV infection are living substantially longer on antiretroviral therapy, but 
hospitalization rates continue to be relatively high. We do not know how overall or diagnosis-
specific hospitalization rates compare between HIV-infected and uninfected individuals or what 
conditions may drive hospitalization trends. Hospitalization rates among United States Veterans 
were calculated and stratified by HIV serostatus and principal diagnosis disease category. Because 
alcohol-related diagnoses (ARD) appeared to have a disproportional effect, we further stratified 
our calculations by ARD history. A multivariable Cox proportional hazards model was fitted to 
assess the relative risk of hospitalization controlling for demographic and other comorbidity 
variables. From 1997–2011, 46,428 HIV-infected and 93,997 uninfected patients were followed 
for 1,497,536 person-years. Overall hospitalization rates decreased among HIV-infected and 
uninfected patients. However, cardiovascular and renal insufficiency admissions increased for all 
groups while gastrointestinal and liver, endocrine, neurologic, and non-AIDS cancer admissions 
increased among those with an alcohol-related diagnosis. After multivariable adjustment, HIV-
infected individuals with an ARD had the highest risk of hospitalization (hazard ratio 3.24, 95%CI 
3.00, 3.49) compared to those free of HIV infection and without an ARD. Still, HIV alone also 
conferred increased risk (HR 2.08, 95%CI 2.04, 2.13). While decreasing overall, risk of all-cause 
hospitalization remains higher among HIV-infected than uninfected individuals and is strongly 
influenced by the presence of an ARD.
Corresponding author and requests for reprints: Christopher Rentsch, VA Connecticut Healthcare System, 950 Campbell Avenue, 
West Haven, CT 06516, Christopher.Rentsch@va.gov, Mobile: +1 770-580-0860, Fax: +1 203-937-4926. 
HHS Public Access
Author manuscript
AIDS Behav. Author manuscript; available in PMC 2017 March 01.
Published in final edited form as:
AIDS Behav. 2016 March ; 20(3): 555–564. doi:10.1007/s10461-015-1025-y.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Keywords
inpatient care; HIV; substance abuse; clinical epidemiology; aging
INTRODUCTION
Since the availability of combination active antiretroviral therapy (ART), aging HIV-
infected (HIV+) patients are increasingly hospitalized for non AIDS-defining conditions, 
such as cardiovascular, cerebrovascular, respiratory, and non-AIDS cancer complications 
(1–6). Although their risk for many of these conditions is increased due to their HIV 
infection (3–5, 7, 8), few recent publications have compared hospitalizations among HIV+ 
individuals with demographically and behaviorally similar uninfected individuals. One 2006 
study from Canada (9) compared hospitalizations among HIV-infected and uninfected 
individuals; none have been conducted in the United States.
Of special note, alcohol abuse, dependence, and other alcohol-related diagnoses (ARD) 
(e.g., alcoholic liver disease, alcoholic gastritis), are common among HIV+ patients (10, 11). 
HIV+ individuals may be particularly susceptible to harm from alcohol for several reasons. 
First, alcohol use decreases adherence to ART (12). Second, alcohol may contribute to 
microbial translocation and may exacerbate the state of chronic inflammation thought to be 
driving an increased risk of many age-associated, non-AIDS conditions among those with 
HIV infection (13). Third, even low levels of alcohol use are associated with hepatic fibrosis 
(14) and can aggravate the harmful effects of HIV infection (15) and of hepatitis C infection 
(16) on the liver. Fourth, continued alcohol use may exacerbate depression (17, 18) and 
other forms of mental illness. Finally, continued alcohol use may interfere with patient’s 
efforts to stop smoking, control hypertension, or proactively manage their healthcare (17, 
19–21).
ARDs are strongly associated with the risk of hospitalization among uninfected populations 
(22), and a recent systematic review showed a variable impact of ARDs on hospitalizations 
among HIV+ persons (23). Half of the reviewed studies suggested a significant increase in 
hospitalizations among HIV+ patients with an ARD compared to those without an ARD 
(23–26); and half reported no association (27–30). An important limitation to these studies 
was the lack of comparison to uninfected populations (1–3, 23). Using United States 
Veterans Administration Healthcare System (VA) data collected on all HIV+ patients in care 
and their uninfected counterparts, we compare hospitalizations by HIV status and ARD 
history, overall and by principal diagnosis from 1997 to 2011.
METHODS
Study Cohort
The Veterans Aging Cohort Study (VACS) has been well described (31, 32). In brief, VACS 
is an ongoing longitudinal study that includes HIV+ patients and an age/race/site-of-care 
matched control group of uninfected patients in care. This analysis included all HIV+ VACS 
patients who initiated care in the VA between October 1, 1996 and December 31, 2011 and 
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their uninfected controls. Hospitalizations were counted after January 1, 1997 and 
hospitalization rates were calculated per calendar year. There were 254 controls who 
seroconverted during follow-up and were removed from these analyses.
The development of VACS has been approved by the Institutional Review Boards of the VA 
Connecticut Healthcare System and Yale University School of Medicine, granted a waiver 
of informed consent, and deemed HIPAA compliant.
Hospitalizations and Alcohol-Related Diagnoses
Hospitalization data were extracted from the national VA electronic medical records, 
Medicare, and Medicaid databases. However, due to the large number of duplicate 
hospitalization records between the Medicare and Medicaid databases among this patient 
population (many of these patients qualify for both Medicare based on disability or age, and 
Medicaid based on income), we did not include data from the Medicaid databases in these 
analyses. Using both unique patient identifiers and hospitalization dates, any further 
duplicate record of a single hospitalization was removed from the analysis. In all instances 
of duplicate hospitalizations, the VA records were kept. A hospitalization was defined as 
any admission that consisted of an overnight stay. For each hospitalization, an International 
Classification of Diseases, Ninth Revision (ICD-9) code was recorded denoting the principal 
diagnosis. We categorized these principal diagnoses to be in concert with previously 
published VACS studies (6, 11, 33) and for those ICD-9 codes not previously explored in a 
VACS study, as suggested in other published studies examining hospitalization (see Table, 
Supplementary Material) (3). A list of the remaining ICD-9 codes were categorized and 
agreed upon by two experienced clinicians (DR and ACJ). ARDs were similarly defined by 
ICD-9 codes (see Table, Supplementary Material). Patients were considered to have an ARD 
if they had either two outpatient diagnoses or one inpatient diagnosis within the VA during 
the study period. This is the standard definition used in VACS.
Variable Definitions
Other data collected were the date of VACS enrollment, age at baseline, sex, race, and 
comorbidities, including hypertension, diabetes, chronic obstructive pulmonary disease 
(COPD), chronic hepatitis B, hepatitis C, liver disease, anemia, non-AIDS cancers (bladder, 
breast, buccal cavity and pharynx, digestive system, endocrine system, eye and orbit, female 
genital system, Hodgkin’s, ill-defined, kidney, leukemia, lung, melanomas, male genital 
system, multiple myeloma, non-epithelial skin, penile, prostate, skin, stomach, testicular, 
ureter, urinary system, urethra), cardiovascular disease (myocardial infarction, coronary 
artery disease, heart failure, transient ischemic attack, peripheral vascular disease, stroke, 
ischemic stroke), drug-related diagnoses, and psychiatric diagnoses (depression, anxiety, 
post-traumatic stress disorder, schizophrenia, schizoaffective disorder). All comorbidities 
were routinely collected within the VACS database using ICD-9 codes (see Table, 
Supplementary Material). The date of diagnosis for each comorbidity was defined as the 
second outpatient date if the patient was seen in an outpatient setting or the discharge date if 
the patient was seen in an inpatient setting. A comorbidity was considered present at cohort 
entry if the diagnosis date occurred before or within one year after VACS enrollment.
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Statistical Analyses
We compared demographic characteristics between HIV+ and uninfected patients using 
two-sided Wilcoxon Rank-Sum (z) and chi-square (χ2) tests (34). Annual hospitalization 
rates were calculated over the study period. For each calendar year, the numerator was the 
number of unique patients active within the healthcare system and hospitalized at least once, 
and the denominator was the total number of unique patients active within the healthcare 
system. We considered a patient to be active within the healthcare system if they had any 
inpatient or outpatient visit in either the VA or Medicare system in the given calendar year. 
A patient could only contribute one hospitalization per year due to a number of patients who 
had an excessive number of repeat admissions for the same condition. When allowing these 
patients to contribute all of their admissions, they heavily influenced higher hospitalization 
rates, especially among psychiatric admissions. Thus, in order to allow equal contributions 
to the annual hospitalization rate regardless of principal diagnosis, we defined the numerator 
as having at least one admission in the given year.
Annual hospitalization rates were stratified by both HIV serostatus and ARD history. We 
then stratified annual hospitalization rates by each of the 12 principal diagnosis categories. 
Ordinary least squares regression models were used to obtain Wald chi-square (χ2) test 
statistics (34), which examined trends in hospitalization rates over the study period.
A multivariable Cox proportional hazards model was used to model the risk of 
hospitalization using both HIV serostatus and ARD as the two primary exposures of interest 
(34). To reduce potential biases from patients who were more likely to be hospitalized at 
cohort entry, only patients who did not experience a hospitalization within the first 180 days 
after VACS enrollment were eligible for this modeling portion of the analysis. The model 
controlled for prognostic factors including age at VACS enrollment, sex, race, comorbidities 
as defined above, and an interaction term between HIV serostatus and ARD history. All 
variables satisfied the proportional hazards assumption, and there was no evidence of 
collinearity (all condition indices <20). Statistical analyses were performed using SAS 
version 9.4 (SAS Institute Inc., Cary, NC, USA). Due to the large number of psychiatric 
hospitalizations, we also conducted a sensitivity analysis omitting these hospitalizations.
RESULTS
There were 46,428 HIV+ and 93,997 uninfected patients who fit the study inclusion criteria 
(n=140,425) and they were followed from 1997 to 2011 (1,497,536 person-years). At 
baseline the median age was 45 years (interquartile range [IQR] 39–51 years); most were 
male (98%); 47% were black/African-American, 39% white/Caucasian, and 7% Hispanic 
(Table I). The most common comorbidities were psychiatric diagnoses (56% among HIV+ 
patients vs. 53% among uninfected patients, χ2=127.1), hypertension (50% among HIV+ 
patients vs. 63% among uninfected patients, χ2=1993.8), ARDs (33% among HIV+ patients 
vs. 31% among uninfected patients, χ2=83.1), and drug-related diagnoses (33% among HIV
+ patients vs. 24% among uninfected patients, χ2=1488.6), and these all differed by HIV 
status (all p<0.0001) (Table I).
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During follow-up, 72% (n=33,600) of HIV+ patients and 58% (n=54,654) of uninfected 
patients were hospitalized (total n=88,254) a total of 545,535 times. The majority (77%) of 
the hospitalizations occurred within the VA while the remaining 23% took place outside of 
the VA (Table II). Among those hospitalized, HIV+ patients experienced a higher median 
number of admissions (4 hospitalizations per patient; IQR 2–8) than uninfected patients (3 
hospitalizations per patient; IQR 1–7) (z=14.0, p<0.0001). However, both HIV+ and 
uninfected patients experienced a median length of stay of five days per admission (IQR 2–
10 days). Hospitalizations with psychiatric diagnoses were the most common in this cohort. 
Of note, only 12% (n=26,045) of admissions among HIV+ patients were categorized as 
HIV/AIDS-related.
Hospitalization rates decreased over the study period for both HIV+ patients (a 32% 
decrease from 304 admissions per 1000 patients in 1997 to 206 admissions per 1000 patients 
in 2011, χ2=1315.9, p-trend <0.0001) and uninfected patients (a 21% decrease from 212 
admissions per 1000 patients in 1997 to 167 admissions per 1000 patients in 2011, χ2=280.9, 
p-trend <0.0001) (Figure 1a). Nearly a third of both HIV+ and uninfected individuals in this 
sample had an ARD at baseline or during follow-up. Hospitalization rates also decreased 
over the study period for those with an ARD (a 21% decrease from 353 admissions per 1000 
patients in 1997 to 279 admissions per 1000 patients in 2011, χ2=443.1, p-trend <0.0001) 
and those without an ARD (a 22% decrease from 170 admissions per 1000 patients in 1997 
to 132 admissions per 1000 patients in 2011, χ2=289.6, p-trend <0.0001) (Figure 1b).
While overall hospitalization rates by HIV serostatus and ARD history decreased between 
1997 and 2011, the stratification of these rates by principal diagnosis category yielded 
contrasting results. Overall, the group at greatest risk for hospitalization was HIV+ 
individuals with an ARDs (Figure 2a). Hospitalizations with psychiatric, HIV/AIDS, ARD, 
and drug-related diagnoses significantly decreased over the study period regardless of HIV 
infection or ARD history (Figures 2b–e; all χ2>150, all p-trend <0.0001). In addition, the 
hospitalization rates within these principal diagnosis categories were the highest among all 
the principal diagnosis categories. Conversely, hospitalizations with cardiovascular and 
renal insufficiency diagnoses significantly increased over the study period regardless of HIV 
infection or ARD history (Figures 2f–g; all χ2>5, all p-trend <0.03).
Hospitalizations in all other categories, which included those with gastrointestinal (GI) and 
liver, endocrine, neurologic, non-AIDS cancer, respiratory, and other infection diagnoses, 
significantly increased among uninfected patients regardless of ARD history (Figures 2h–m; 
all χ2>16, all p-trend <0.0001). While ARD history did not appear to be important among 
uninfected individuals for these hospitalizations, HIV+ individuals with an ARD 
experienced higher rates than HIV+ individuals without an ARD. For instance, 
hospitalizations with a GI and liver or an endocrine diagnosis increased significantly among 
HIV+ patients with an ARD (GI and liver: χ2=6.4, p-trend=0.01; endocrine: χ2=7.4, p-trend 
<0.01) but decreased among HIV+ patients without an ARD (GI and liver: χ2=14.5, p-trend 
<0.0001; endocrine: χ2=27.5, p-trend <0.0001). Furthermore, hospitalizations with 
neurologic or non-AIDS cancer diagnoses increased significantly among HIV+ patients with 
an ARD (neurologic: χ2=76.8, p-trend <0.0001; non-AIDS cancer: χ2=186.8, p-trend 
<0.0001) but there were no detected trends among HIV+ patients without an ARD 
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(neurologic: χ2=0.6, p-trend=0.43; non-AIDS cancer: χ2=0.1, p-trend=0.77). Among HIV+ 
patients, respiratory hospitalization rates showed no significant change over the study period 
among those with an ARD (χ2=0.06, p-trend=0.83) but decreased among those without an 
ARD (χ2=155.9, p-trend <0.0001). Finally, hospitalizations among HIV+ patients related to 
other infections decreased significantly regardless of ARD history (χ2>6, p-trend <0.01).
The multivariable model (Table III) assessed the risk of hospitalization between HIV+ and 
uninfected patients who did not experience an admission for at least 180 days after VACS 
enrollment. The distribution of principal diagnoses for these patients’ first hospitalization 
was: 13% cardiovascular, 12% psychiatric, 10% GI and liver, 9% neurologic, 8% for each 
non-HIV/AIDS infection and respiratory, 6% for each ARD and drug-related diagnoses, 5% 
HIV/AIDS, 4% non-AIDS cancer, and 3% for each endocrine and renal insufficiency. In 
multivariable analyses comparing to uninfected patients without an ARD, both an HIV 
infection (adjusted hazard ratio [aHR] 1.85, 95% confidence interval [95%CI] 1.81, 1.88) 
and an ARD (aHR 2.08, 95%CI 2.04, 2.13) increased the risk of hospitalization. 
Furthermore, those who were HIV+ with an ARD were over three times as likely to be 
admitted than their uninfected with no ARD counterparts (aHR 3.24, 95%CI 3.00, 3.49).
The sensitivity analyses omitted all psychiatric diagnoses-related hospitalizations. While p-
values and proportions changed, all significant findings made when these hospitalizations 
were included remained (data not shown).
DISCUSSION
Since ART became available in 1996 and through 2011, overall hospitalization rates have 
declined 32% for HIV+ patients (from 304 to 206 per 1000 patients) and 21% (from 212 to 
167 per 1000 patients) for uninfected patients. While overall hospitalizations among HIV+ 
individuals remained higher than among uninfected individuals, the excess risk dropped 
from 43% (304/212 per 1000 patients in 1996) to 23% (206/167 per 1000 patients in 2011). 
In contrast, the excess risk for patients with an ARD versus those without an ARD remained 
high over the study period starting at 108% (353/170 per 1000 patients in 1997) and ending 
at 111% (279/132 per 1000 patients in 2011). Importantly, HIV infection and ARDs had 
additive effects.
Overall hospitalization rates decreased, mostly driven by decreases in hospitalization with 
psychiatric, HIV/AIDS, ARD, and drug-related diagnoses. In contrast, hospitalizations with 
cardiovascular and renal insufficiency diagnoses increased among all groups regardless of 
HIV serostatus or ARD history. Our results should not be interpreted as evidence that HIV 
infection is no longer “important.” Rather, they suggest that people aging with HIV infection 
are particularly susceptible to harm from other chronic conditions like alcohol abuse, 
dependence, and other ARDs. This conclusion is supported by the more pronounced effects 
of ARDs among those with HIV infection seen for GI and liver, endocrine, neurologic, and 
non-AIDS cancer hospitalizations.
During the last year of follow up, HIV+ patients with an ARD had the highest rates of 
admission for psychiatric (72 per 1000 patients), drug-related (49 per 1000 patients), GI and 
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liver (47 per 1000 patients), and alcohol-related (39 per 1000 patients) diagnoses. While this 
may not be surprising, it underscores the importance of addressing modifiable risk factors, 
such as alcohol and drug abuse, if we are to decrease morbidity and mortality associated 
with liver disease, a leading cause of death among those with HIV infection.
Overall, ARDs were common and added to the risk of hospitalization among those with HIV 
infection in unadjusted and adjusted analyses. It is particularly interesting that HIV+ 
individuals with ARD had the most rapid rise in non-AIDS cancer admissions and were 
experiencing the highest rates of admission with cancer diagnoses in the last five years of 
follow-up, from 2007 to 2011. Likely contributing causes include the higher prevalence of 
hepatitis C among HIV+ individuals compared with uninfected individuals (35) and their 
added susceptibility to liver cancer (especially in the context of ongoing heavy alcohol 
consumption) (36, 37). Additionally, heavy alcohol use is associated with heavy tobacco use 
(38) so ARD is also likely associated with increased rates of lung and bladder cancer. 
Perhaps less well appreciated is the direct association of alcohol with other forms of cancer 
including colorectal cancer, breast cancer, oral cavity and pharyngeal cancer. Of note, even 
moderate use of alcohol may increase the risk of many of these cancers (39, 40). 
Importantly, while HIV remains a chronic infection, unhealthy alcohol use (41) is 
modifiable (42–45) through comprehensive treatment programs (46–48).
A potential limitation of this study was the predominantly male United States Veteran 
cohort, which may not be generalizable to other HIV populations. However, when 
comparing VACS data with data from the United States Centers for Disease Control and 
Prevention, VACS subjects were similar with respect to race/ethnicity and risk factors for 
HIV infection (49). Further, VACS data and outcomes have been compared to more than 20 
HIV cohort studies in North America and Europe through collaborations with the 
Antiretroviral Therapy Cohort Collaboration (ART-CC) (50), the HIV-CAUSAL 
Collaboration (51), and the North American AIDS Cohort Collaboration on Research and 
Design (NA-ACCORD) (52). Routine cross-cohort analyses require that analyses be 
stratified by cohort prior to combining data. In all cases, relationships among variables in 
VACS were consistent with data from other cohorts within these collaborations and thus 
were included in joint analyses. Nevertheless, VACS under-represents women and 
hospitalization rates among women should be compared by HIV serostatus in future work.
Also of note, this analysis does not address the underlying causes of ARDs. Prior literature 
suggests that these are myriad among those with and without HIV infection, but among 
those with HIV infection, some issues (e.g., stigma, social isolation, and self-medication) 
may be more pronounced. Similarly, due to the greater prevalence of hepatitis C infection 
among HIV+ individuals, it is possible that some of the increased risk of hospitalization 
overall and for diagnosis-specific rates were due to hepatitis C co-infection.
CONCLUSIONS
Hospitalization rates from 1997 to 2011 have decreased among HIV+ and uninfected 
individuals. ARDs were common in both groups. While decreasing overall, risk of 
hospitalization remains higher among HIV+ individuals than uninfected individuals and is 
Rentsch et al. Page 7
AIDS Behav. Author manuscript; available in PMC 2017 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
strongly influenced by the presence or absence of an ARD. Using effective comprehensive 
treatment programs to treat ARDs and their associated conditions, including psychiatric 
disease, could reduce inpatient utilization and overall morbidity in both HIV+ and 
uninfected patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Hospitalization rates per 1000 at-risk patients enrolled in VACS from 1997 to 2011
VACS – Veterans Aging Cohort Study; HIV – human immunodeficiency virus; ARD – 
alcohol-related diagnosis
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Figure 2. 
Diagnosis-specific hospitalization rates per 1000 at-risk patients enrolled in VACS from 
1997 to 2011 by HIV serostatus and ARD history
VACS – Veterans Aging Cohort Study; HIV – human immunodeficiency virus; ARD – 
alcohol-related diagnosis; GI – gastrointestinal; AIDS – acquired immune deficiency 
syndrome
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Table II
Hospitalization characteristics by HIV serostatus between 1997 and 2011
Covariate HIV-infected (n=214,815) Uninfected (n=330,720) Test statistic Pa
Hospitalizations
 System
  Internal (VA) 77.1% (165,621) 76.7% (253,636) 12.7 0.0004
  External (Medicare) 22.9% (49,227) 23.3% (77,174)
 Median length of stay per hospitalization, days 5 (2–10) 5 (2–10) 13.8 <0.0001
 Primary admission diagnosis category
  Psychiatric 13.1% (28,233) 19.9% (65,884) 4191.4 <0.0001
  HIV/AIDS 12.1% (26,045) - -
  Cardiovascular 7.8% (16,774) 13.5% (44,735) 4256.2 <0.0001
  GI and liver 8.4% (18,031) 8.3% (27,458) 1.4 0.2342
  ARD 6.0% (12,844) 9.3% (30,593) 1901.7 <0.0001
  Drug-related 8.7% (18,655) 7.3% (23,975) 372.2 <0.0001
  Other infection 10.2% (21,964) 5.8% (19,236) 3624.6 <0.0001
  Respiratory 8.5% (18,195) 6.4% (21,228) 817.4 <0.0001
  Neurologic 5.8% (12,344) 7.6% (24,985) 668.1 <0.0001
  Endocrine 2.9% (6,308) 3.7% (12,366) 253.8 <0.0001
  Renal insufficiency 3.1% (6,642) 3.0% (9,924) 3.7 0.0550
  Non-AIDS cancer 2.7% (5,724) 3.1% (10,252) 86.8 <0.0001
  Other 10.7% (23,056) 12.1% (40,084) 244.9 <0.0001
Abbreviations: VACS - Veterans Aging Cohort Study; HIV - human immunodeficiency virus; VA - Veterans Affairs Healthcare System; AIDS - 
acquired immune deficiency syndrome; GI - gastrointestinal; ARD - alcohol-related diagnosis
Note: all percentages based on total number of hospitalizations within each group and reported as %(n); continuous variables reported as median 
(interquartile range)
aAll tests for significance used chi-square (χ2) with degrees of freedom = 1, except for years to hospitalization, number of hospitalizations, and 
length of stay, which used two-sided Wilcoxon Rank-Sum tests (z)
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Table III
Multivariate results for risk to first hospitalization
Covariate Adjusted HR (95% CI)
HIV and ARD categories
 HIV+/ARD+ 3.24 (3.00, 3.49)
 HIV+/ARD- 1.85 (1.81, 1.88)
 HIV-/ARD+ 2.08 (2.04, 2.13)
 HIV-/ARD- ref
Baseline year 0.95 (0.95, 0.96)
Age at baseline 1.03 (1.03, 1.03)
Male sex 0.90 (0.86, 0.95)
Race and ethnicity
 African-American/Black 1.05 (1.03, 1.07)
 Hispanic 0.89 (0.86, 0.91)
 Other/unknown 0.55 (0.53, 0.58)
 Caucasian/White ref
Baseline comorbidity
 Psychiatric 1.27 (1.24, 1.30)
 Hypertension 1.07 (1.05, 1.10)
 Drug-related 1.21 (1.18, 1.25)
 Anemia 1.76 (1.66, 1.86)
 Hepatitis C 1.18 (1.11, 1.25)
 Cardiovascular 1.74 (1.67, 1.81)
 Diabetes 1.34 (1.29, 1.38)
 COPD 1.53 (1.45, 1.61)
 Non-AIDS cancer 1.38 (1.30, 1.46)
 Chronic hepatitis B 1.47 (1.33, 1.64)
 Liver disease 2.04 (1.81, 2.30)
Abbreviations: HR - hazard ratio; CI - confidence interval; HIV - human immunodeficiency virus; ARD - alcohol-related diagnosis; ref - referent 
group; COPD - chronic obstructive pulmonary disorder; AIDS - acquired immune deficiency syndrome
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